These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37945970)

  • 1. Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8
    van der Wulp W; Remst DFG; Kester MGD; Hagedoorn RS; Parren PWHI; van Kasteren SI; Schuurman J; Hoeben RC; Ressing ME; Bleijlevens B; Heemskerk MHM
    Cancer Gene Ther; 2024 Jan; 31(1):58-68. PubMed ID: 37945970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells.
    van der Wulp W; Gram AM; Bleijlevens B; Hagedoorn RS; Araman C; Kim RQ; Drijfhout JW; Parren PWHI; Hibbert RG; Hoeben RC; van Kasteren SI; Schuurman J; Ressing ME; Heemskerk MHM
    Front Immunol; 2023; 14():1183914. PubMed ID: 37261346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of Tumors for Attack by Virus-Specific CD8+ T-Cells Through Antibody-Mediated Delivery of Immunogenic T-Cell Epitopes.
    Sefrin JP; Hillringhaus L; Mundigl O; Mann K; Ziegler-Landesberger D; Seul H; Tabares G; Knoblauch D; Leinenbach A; Friligou I; Dziadek S; Offringa R; Lifke V; Lifke A
    Front Immunol; 2019; 10():1962. PubMed ID: 31555260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8
    Jung K; Son MJ; Lee SY; Kim JA; Ko DH; Yoo S; Kim CH; Kim YS
    Mol Cancer; 2022 Apr; 21(1):102. PubMed ID: 35459256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
    Millar DG; Ramjiawan RR; Kawaguchi K; Gupta N; Chen J; Zhang S; Nojiri T; Ho WW; Aoki S; Jung K; Chen I; Shi F; Heather JM; Shigeta K; Morton LT; Sepulveda S; Wan L; Joseph R; Minogue E; Khatri A; Bardia A; Ellisen LW; Corcoran RB; Hata AN; Pai SI; Jain RK; Fukumura D; Duda DG; Cobbold M
    Nat Biotechnol; 2020 Apr; 38(4):420-425. PubMed ID: 32042168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
    Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
    J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
    Zhang S; Yan C; Millar DG; Yang Q; Heather JM; Langenbucher A; Morton LT; Sepulveda S; Alpert E; Whelton LR; Zarrella DT; Guo M; Minogue E; Lawrence MS; Rueda BR; Spriggs DR; Lu W; Langenau DM; Cobbold M
    Cancer Res; 2022 Mar; 82(5):773-784. PubMed ID: 34965933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus strain heterogeneity impairs human T-cell immunity.
    Cirac A; Stützle S; Dieckmeyer M; Adhikary D; Moosmann A; Körber N; Bauer T; Witter K; Delecluse HJ; Behrends U; Mautner J
    Cancer Immunol Immunother; 2018 Apr; 67(4):663-674. PubMed ID: 29374782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.
    Rist MJ; Neller MA; Burrows JM; Burrows SR
    J Virol; 2015 Jan; 89(1):703-12. PubMed ID: 25355876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDR3α drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection.
    Kamga L; Gil A; Song I; Brody R; Ghersi D; Aslan N; Stern LJ; Selin LK; Luzuriaga K
    PLoS Pathog; 2019 Nov; 15(11):e1008122. PubMed ID: 31765434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells.
    Kuzushima K; Hayashi N; Kudoh A; Akatsuka Y; Tsujimura K; Morishima Y; Tsurumi T
    Blood; 2003 Feb; 101(4):1460-8. PubMed ID: 12393434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor α and β Repertoires.
    Gil A; Kamga L; Chirravuri-Venkata R; Aslan N; Clark F; Ghersi D; Luzuriaga K; Selin LK
    mBio; 2020 Mar; 11(2):. PubMed ID: 32184241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection.
    Catalina MD; Sullivan JL; Bak KR; Luzuriaga K
    J Immunol; 2001 Oct; 167(8):4450-7. PubMed ID: 11591771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection.
    Khan N; Hislop A; Gudgeon N; Cobbold M; Khanna R; Nayak L; Rickinson AB; Moss PA
    J Immunol; 2004 Dec; 173(12):7481-9. PubMed ID: 15585874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and functional heterogeneity of EBV epitope-specific CD8+ T cells.
    Catalina MD; Sullivan JL; Brody RM; Luzuriaga K
    J Immunol; 2002 Apr; 168(8):4184-91. PubMed ID: 11937579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A11 Tetramer-assisted characterization of Rta-specific CD8+ T-cell responses in healthy virus carriers.
    Yu HX; Srinivasan N; Ren EE; Chan SH
    Tissue Antigens; 2005 Jun; 65(6):539-43. PubMed ID: 15896201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.